Intravitreal Aflibercept for Retinal Angiomatous Proliferation : Results of a prospective case series at 96 weeks

Browning, Andrew C.O'Brien, Jill M.Vieira, Rute V.Gupta, RajenNenova, Kapka2019-06-132019-06-132019Browning, A C, O'Brien, J M, Vieira, R V, Gupta, R & Nenova, K 2019, 'Intravitreal Aflibercept for Retinal Angiomatous Proliferation : Results of a prospective case series at 96 weeks', Ophthalmologica, vol. 242, no. 4, pp. 239-246. https://doi.org/10.1159/0005002030030-3755Mendeley: d6ffde97-8c5d-37bb-acdb-560a83032256http://hdl.handle.net/2164/123868245047engRetinal angiomatous proliferationNeovascular age-related macular degenerationAfliberceptRISK-FACTORSPHOTODYNAMIC THERAPYMACULAR DEGENERATIONVERTEPORFINFELLOW EYENEOVASCULARIZATIONTRIAMCINOLONERANIBIZUMABGEOGRAPHIC ATROPHYENDOTHELIAL GROWTH-FACTORRE OphthalmologySensory SystemsOphthalmologyREIntravitreal Aflibercept for Retinal Angiomatous Proliferation : Results of a prospective case series at 96 weeksJournal article10.1159/000500203https://www.karger.com/Journal/Guidelines/224269#sec72http://www.scopus.com/inward/record.url?scp=85067003029&partnerID=8YFLogxKhttp://www.mendeley.com/research/intravitreal-aflibercept-retinal-angiomatous-proliferation-results-prospective-case-series-96-weeks2424